Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 36.9% in March

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 1,250,000 shares, a decrease of 36.9% from the February 28th total of 1,980,000 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 2,640,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On Cardio Diagnostics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in shares of Cardio Diagnostics in the 4th quarter valued at approximately $236,000. Jane Street Group LLC purchased a new position in Cardio Diagnostics in the fourth quarter worth approximately $103,000. Two Sigma Securities LLC acquired a new stake in Cardio Diagnostics during the fourth quarter worth $48,000. Finally, Geode Capital Management LLC raised its position in Cardio Diagnostics by 97.6% in the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after purchasing an additional 179,978 shares during the period. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Stock Down 8.1 %

Shares of NASDAQ CDIO traded down $0.03 during trading on Friday, hitting $0.38. 1,509,670 shares of the company were exchanged, compared to its average volume of 2,533,523. The company has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.48. Cardio Diagnostics has a 12-month low of $0.19 and a 12-month high of $1.77.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.